Replies to post #68719 on NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Senti getting shuteye(Calif): I just got 2 hrs so I'll respond:
Convoluted intentionally maligned story set up by AFraudstein that did BIG DAMAGE:
As can be seen here: http://www.nwbio.com/nw-bio-has-initiated-its-dcvax-direct-phase-iii-trial-for-all-solid-tumor-cancers-2/

According to the primary investigator, Dr. Vivek Subbiah, MD (Assistant Professor in the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine,

Politically and professionally concerned prominent Dr.Buzdar stepped out of line in responding when he has a major vested interest in use of Chemotherapy:see http://www.breastcancer.org/about_us/pab/aman_u_buzdar:
http://faculty.mdanderson.org/aman_buzdar/

He is also deputy department chairman in the department of breast medical oncology there, and an associate editor of the journal Clinical Cancer Research. His research interest lies in improving and defining short- and long-term benefits of chemotherapy, and he is testing several new hormonal therapies in the treatment of breast cancer.

Hopefully everyone who is new to NWBO NOW should understand: Chemo does impact the immune system hence Dr. Budzar was quoted by AFraudstein when professionally Dr. Budzar took the unprecedented step in speaking about a trial that he was not even involved in and clearly has more political clout internally than Dr. Vivek Subbiah who because of his lesser stature internally has been cordoned off from commentary other than when results should be announced.
Moreover Dr. Budzar was the PI for a key Chemo drug which name currently escapes me.

The above plus the luminary Hd of Oncology dept of MDAnderson with it's longstanding Moonshot Program funded by Big Rx probably also had a heavy hand in this first MAJOR Skirmish faced by CEO LP.

PS: Longfellow... re Opdivo: We ARE on the same wavelength and I maybe off at times:no scientific background see my response to Branko:http://investorshub.advfn.com/boards/replies.aspx?msg=124301308

The MD Anderson DIRECT trial experience as done by Manipulator AFraudstein struck a MAJOR BLOW to the shares: the shorts PRIOR to that event were LOSING $lots along with key stock momentum. But AFraudstein with his devious deployment dealt a vital REVERSAL: of course everyone here was FUMING: I wasn't totally shocked: VICIOUS jungular methodology just like Phase V tome with anonymous author.

[exwannabe]

Do we know whether or not Buzdar was MD Anderson site investigator?

Buzdar is VP of clinical research at MD Anderson.
From the org chart:

VP, Clinical Research Administration reports to the vice provost of clinical and interdisciplinary research and oversees the institutional infrastructure for clinical research.He maximizes opportunities to advance the quality of the clinical research while adhering to the highest standards of clinical research compliance. He serves as advocate for clinical investigators with regard to policies and processes governing the performance of clinical research.

So, per his job title he is the person responsible for speaking on behalf of the trial investagor. Sounds like the direct trial issue would have been specifically in his job title.

The issue BTW was not about trial results being released on an inertum basis per se, but about LP jumping the gun on the trial investigator.

Regardless, the skirmish works out for the best for LP as it gives her an excuse to never release the real results, just bits of data.